1 · Case at a Glance
§ SUMMARYBorn 17 Apr 2026 at 16:20 at 29 +0/7 weeks GA, birth weight 1310 g. Cried twice at delivery, but had recurrent apnea attributed to apnea of prematurity. Immediately intubated in the delivery room and transferred to NICU on a Hamilton-G5 ventilator in P-CMV mode.
The first venous blood gas at ~3 h of life demonstrated severe mixed acidosis: pH 7.022, pCO₂ 127.9 mmHg, HCO₃⁻ 33.2 mmol/L, on FiO₂ 40 %.
Empiric antibiotics were started on Day 1 (Penicillin G "Polypen" + Amikacin) and have since been escalated twice — first to Piperacillin-Tazobactam ("Vigocid") on Day 7, then to Meropenem ("Meromax") on Day 11.
Despite 16 days of mechanical ventilation and antibiotic escalation, the infant remains ventilator-dependent with persistent permissive-range to severe hypercapnia (recent ABGs: pCO₂ 90.8 → 105.4 mmHg). pH is partially compensated through striking renal bicarbonate retention (HCO₃⁻ now 48.7 mmol/L, BE +21.6) — a pattern consistent with chronic respiratory acidosis.
Chest x-rays show a biphasic course: initial right paracardiac haziness (4/17), partial clearing (4/22), then interval progression to bilateral hazy-streaky opacities by 4/27.
Blood culture drawn at admission was negative at 5 days. CRP normalized from 28.6 → 2.75 mg/L by Day 4. There is no microbiological evidence of bacteraemia, yet antibiotics continue to be escalated.
2 · Specific Clinical Concerns
§ CONCERNSFor a 29-week preterm with respiratory failure requiring intubation in the delivery room, exogenous surfactant (poractant alfa, beractant, or calfactant) is widely considered standard of care for established or impending respiratory distress syndrome (RDS). The 2022 European Consensus Guidelines on Management of RDS recommend early rescue surfactant for any preterm infant requiring intubation for RDS. No surfactant product appears in the itemized billing from 17 Apr through 26 Apr.
Methylxanthine therapy (caffeine citrate) is a Cochrane-supported, AAP-endorsed standard of care for preterm infants <32 weeks. It treats apnea of prematurity, has been shown to reduce the duration of mechanical ventilation and rates of bronchopulmonary dysplasia (CAP trial, NEJM 2006), and is typically initiated within the first 72 hours. Despite this infant's documented apnea of prematurity at delivery (the stated indication for intubation), no caffeine citrate / Cafcit / Peyona is documented in the billing record.
A haemodynamically significant patent ductus arteriosus (hsPDA) is among the most common reversible causes of failure to wean from mechanical ventilation in this population. Persistent hypercapnia, worsening bilateral pulmonary opacities, and ventilator dependence beyond 7–10 days are textbook indications for echocardiographic evaluation. Billing data shows a cranial ultrasound on 21 Apr (presumably for IVH screening) but no echocardiogram. PDA cannot be confirmed or excluded clinically alone.
Initial empiric coverage (Penicillin G + Amikacin) was reasonable. However:
- Blood culture drawn 17 Apr 19:47 returned no growth at 5 days (validated 23 Apr).
- CRP fell from 28.6 mg/L (18 Apr) to 2.75 mg/L (21 Apr) — within normal range.
- Despite this, antibiotics were escalated to Piperacillin-Tazobactam on 23 Apr and to Meropenem ("Meromax") on 27–28 Apr.
Reviewers should comment on whether continued antibiotic exposure is justified, what cultures (tracheal aspirate, repeat blood, urine) have been obtained, and whether a non-infectious cause for the worsening x-ray is being adequately evaluated.
The infant has remained on P-CMV (pressure control, time-cycled) for the entire 16-day course on the Hamilton G5. Modern neonatal ventilation typically favours a volume-targeted mode (e.g., PSV + Volume Guarantee, PRVC, or APV-CMV / APVsimv on the G5) which has Cochrane evidence for reduced rates of pneumothorax, BPD, severe IVH, and duration of ventilation. Tidal-volume monitoring shows substantial variability (Vte/kg ranging 7.3 – 15.7 mL/kg) — both volutrauma (high) and atelectotrauma (low) ranges are present. Reviewers may wish to comment on optimal mode selection.
Radiology described "interval progression of hazy and streaky opacities now involving both lung fields" on 27 Apr. The differential at this PMA and ventilator duration includes evolving BPD, ventilator-associated pneumonia, atelectasis, pulmonary oedema (PDA-related), pulmonary haemorrhage, and air-leak. A repeat CXR after 27 Apr is not present in the available data. No CT, no echocardiogram, no tracheal aspirate culture has been documented to clarify the aetiology.
3 · Clinical Timeline
§ TIMELINE4 · Blood Gases — pH, pCO₂, HCO₃⁻, Base Excess
§ ABG / VBGHypercapnia (pCO₂ > 55–60 mmHg) reflects inadequate alveolar ventilation. In acute respiratory acidosis the kidneys have not had time to compensate, so the pH falls. Chronic respiratory acidosis is characterised by progressive renal HCO₃⁻ retention (≈ 0.35 mmol/L rise in HCO₃⁻ for every 1 mmHg sustained rise in pCO₂). This patient's HCO₃⁻ has climbed from 33 → 48.7 mmol/L and BE from +2.2 → +21.6 over 16 days — the textbook fingerprint of chronic CO₂ retention. The pH is therefore "near-normal" but the underlying ventilatory failure is persistent and worsening.
5 · Ventilator Settings & Monitored Values
§ HAMILTON G56 · Chest X-Ray Reports
§ RADIOLOGYFrom 17 Apr to 22 Apr the films showed initial right paracardiac haze attributed to retained fetal lung fluid, then partial clearing. By 27 Apr (5 days later) the radiologist noted interval progression now involving both lung fields. No further imaging appears in the available record.
📄 View full radiologist reports (verbatim)
7 · Other Laboratory Data
§ LABS8 · Medications & Respiratory-Relevant Items
§ PHARMACY9 · Procedures & Diagnostics Performed
§ PROCEDURES10 · Working Differential for Refractory Hypercapnia
§ DIFFERENTIAL1. Evolving Bronchopulmonary Dysplasia (BPD). Persistent oxygen requirement, ventilator dependence beyond 28 days of life, characteristic CXR progression to diffuse hazy opacities. PMA at first definition of BPD is 36 weeks; this infant is currently 31 +1/7 wk PMA so this would be "evolving."
2. Haemodynamically significant PDA. Has not been imaged. Can cause pulmonary over-circulation, increased extravascular lung water, atelectasis, and ventilator dependence. Classic timing — symptoms emerge around end of first week as PVR drops. Urgent echocardiogram indicated.
3. Surfactant deficiency / RDS not adequately treated. No surfactant administered → would explain the very high initial pCO₂ (127.9) and persistently poor compliance.
4. Ventilator-associated pneumonia (VAP). Worsening bilateral CXR despite negative initial blood culture. Tracheal aspirate culture would be informative.
5. Atelectasis / mucus plugging. P-CMV with low Vte values (~7 mL/kg) on some readings, prolonged immobility. Suctioning is documented but its effectiveness is not assessed in the available data.
6. ETT malposition / size mismatch. Initial CXR noted ETT tip 0.4 cm from carina with retraction recommended; follow-up films do not state position. A 2.5–3.0 mm uncuffed tube was billed (consistent with size for weight), but ongoing position should be confirmed on every CXR.
7. Air-leak / pulmonary interstitial emphysema (PIE). Not seen on the available reports but a known complication of P-CMV without volume targeting. Lateral CXR recommended if progression continues.
8. Central hypoventilation / sedation effect. No sedative/opioid is listed in the visible billing, but the absence of caffeine (a respiratory stimulant) is a relevant negative.
9. Pulmonary haemorrhage. Would typically be more dramatic but worth ruling out via tracheal aspirate inspection.
10. Congenital anomaly (CDH, CCAM, lobar emphysema). Less likely given the radiology has been read as fluid/inflammatory pattern, but a formal review of the films by a paediatric radiologist is worth obtaining.
- Functional echocardiography (PDA, pulmonary hypertension, cardiac function)
- Repeat CXR (PA & lateral)
- Lung ultrasound
- Cranial ultrasound (already done 21 Apr — repeat if not recently)
- Tracheal aspirate culture & gram stain
- Repeat blood culture
- Urine culture
- Viral panel (RSV, influenza, etc.)
- Caffeine citrate loading dose + maintenance
- Late surfactant rescue (if compliance still poor)
- Switch to volume-targeted mode (e.g., APV-CMV with VT 4–5 mL/kg)
- Consider HFOV trial if conventional fails
- Diuretic trial if PDA / fluid overload confirmed